ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled the first patient in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD). The randomized, double blind, and placebo-controlled study will recruit up to 300 patients and will be conducted at 40 sites in the United States. Serdaxin will be administered as an oral, extended release tablet. Patient enrollment will occur through the first half of 2011, with preliminary data expected in late 2011.
